TUFM Antibody

What is TUFM and what biological functions does it serve in cellular processes?

TUFM is a 452 amino acid protein that contains a tr-type G (guanine nucleotide-binding) domain and belongs to the TRAFAC class translation factor GTPase superfamily. This protein serves multiple critical functions in cellular biology:

• Primarily promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during mitochondrial protein biosynthesis

• Functions in autophagy regulation and innate immunity as a checkpoint molecule

• Recruits ATG5-ATG12 and NLRX1 at mitochondria, serving as a checkpoint of the RIGI-MAVS pathway

• Inhibits RLR-mediated type I interferon while promoting autophagy processes

• Plays a role in mitochondrial biogenesis and function, as demonstrated in zebrafish studies

TUFM shows subcellular localization specifically to the mitochondria, with observed molecular weights typically between 46-50 kDa in laboratory applications. The protein's involvement in multiple cellular pathways makes it an important target for research in mitochondrial disorders, cancer biology, and immunological studies.

What experimental applications are TUFM antibodies validated for in research settings?

TUFM antibodies have been extensively validated for multiple research applications through rigorous testing protocols:

The extensive validation across these applications makes TUFM antibodies versatile tools for investigating this protein's expression, interactions, and functions in diverse experimental contexts.

What considerations are important when selecting a TUFM antibody for specific experimental purposes?

When selecting a TUFM antibody, researchers should evaluate several critical parameters to ensure experimental success:

• Antibody type: Consider whether a monoclonal (more specific, consistent) or polyclonal (broader epitope recognition) antibody best suits your application. For example, monoclonal antibody 67802-1-Ig provides higher specificity for Western blotting with recommended dilutions of 1:5000-1:50000, while polyclonal 26730-1-AP offers broader epitope recognition at 1:1000-1:8000 dilutions .

• Species reactivity: Verify compatibility with your experimental model. Most TUFM antibodies react with human, mouse, and rat samples, while some have been cited for zebrafish reactivity .

• Application-specific validation: Ensure the antibody has been validated specifically for your application. For example, for immunohistochemistry applications, antibodies should be verified with appropriate antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0) .

• Clone/catalog identification: Reference the specific clone or catalog number in publications to ensure reproducibility. Commercial antibodies like 26730-1-AP or 67802-1-Ig have unique identifiers and RRID numbers (AB_2880616, AB_2918565) for accurate citation .

• Target epitope location: Consider whether the epitope location might affect recognition in your experimental system, particularly if studying protein domains or splice variants.

Careful selection based on these parameters will significantly improve experimental outcomes and data reliability.

How should optimization protocols be designed for different TUFM antibody applications?

Methodological optimization for TUFM antibody applications requires systematic approach tailored to each technique:

For Western Blotting optimization:

• Begin with titratable dilution ranges based on antibody type: 1:1000-1:8000 for polyclonal (26730-1-AP) or 1:5000-1:50000 for monoclonal (67802-1-Ig) antibodies

• Include validated positive controls: A431 cells, Jurkat cells, brain tissue extracts show consistent TUFM expression

• Adjust protein loading to 10-30μg total protein based on expression levels

• Optimize transfer conditions for the 46-50 kDa molecular weight range

• For challenging samples, consider extended blocking (5% BSA or milk for 1-2 hours) and overnight primary antibody incubation at 4°C

For Immunohistochemistry optimization:

• Critical antigen retrieval step: Compare TE buffer pH 9.0 (preferred) with citrate buffer pH 6.0 to determine optimal epitope exposure

• Test dilution ladders: 1:400, 1:800, 1:1600 for polyclonal antibodies; 1:1000, 1:2000, 1:4000 for monoclonal antibodies

• Include positive control tissues with known TUFM expression (human stomach, colon cancer tissue)

• Optimize detection systems: Compare HRP/DAB with other chromogens for sensitivity and specificity

• Consider tissue-specific background issues and adjust blocking protocols accordingly

For Immunofluorescence optimization:

• Test fixation/permeabilization combinations: PFA/Triton X-100 has shown consistent results

• Establish signal-to-noise ratios across dilutions from 1:500-1:2000

• Verify mitochondrial colocalization using established markers (MitoTracker, TOM20)

• Implement z-stack acquisition for accurate subcellular localization assessment

• Document exposure settings and microscope parameters for reproducibility

Systematic optimization with proper documentation ensures consistent, reproducible results across experiments.

What validation strategies confirm TUFM antibody specificity and prevent false-positive interpretation?

Comprehensive validation of TUFM antibodies requires multiple complementary approaches:

• Western blot molecular weight verification: Confirm single band at expected 46-50 kDa range across multiple cell types. The observed molecular weight has been consistently reported between 46-50 kDa in various cell lines, including A431, Jurkat, HepG2, and HeLa .

• Multi-antibody concordance testing: Compare staining patterns using antibodies targeting different TUFM epitopes. For example, comparing polyclonal (26730-1-AP) with monoclonal (67802-1-Ig) antibody patterns can verify consistent localization patterns .

• Genetic knockdown validation: Implement siRNA or CRISPR-mediated TUFM depletion to confirm signal reduction. This KO validation approach has been cited for certain TUFM antibodies .

• Peptide competition assays: Pre-incubate antibody with immunizing peptide/recombinant protein to demonstrate specific binding inhibition.

• Subcellular fractionation correlation: Verify enrichment in mitochondrial fractions consistent with known TUFM localization.

• Cross-species reactivity patterns: Confirm expected conservation patterns across human, mouse, and rat samples that align with evolutionary conservation .

• Multi-application concordance: Verify consistent detection in WB, IHC, and IF applications from the same samples.

• Mass spectrometry validation: For definitive validation, confirm IP-enriched protein identity through MS analysis.

Implementing multiple validation approaches provides the highest confidence in antibody specificity and experimental results.

How does TUFM expression differ between normal and diseased tissues, particularly in cancer models?

Significant TUFM expression differences have been documented between normal and pathological tissues:

In glioblastoma multiforme (GBM):

• Differential upregulation of TUFM has been observed in GBM cell lines and primary tumors compared to neural stem cells and normal brain tissue at both protein and mRNA levels

• This differential expression pattern has been leveraged for targeted therapy approaches using anti-TUFM nanobodies (Nb206) with specificity for GBM stem cells versus normal cells

• Immunohistochemical analysis showed nearly 100% of GBM cells stained positively with both Nb206 and conventional anti-TUFM antibodies

In other cancer types:

• IHC analysis has demonstrated TUFM expression in human esophageal cancer tissues

• TUFM has been detected in various cancer cell lines including MCF7 (breast cancer), U-2 OS (osteosarcoma), and HepG2 (liver cancer)

• TUFM may participate in mitochondrial translation processes that support altered metabolism in cancer cells

In normal tissues:

• TUFM shows consistent expression across human duodenum, endometrium, kidney, and testis tissues with similar distribution patterns detected by independent antibodies

• Brain tissue consistently shows detectable TUFM expression in both human and rodent models

These differential expression patterns suggest potential diagnostic and therapeutic applications, particularly in glioblastoma and other cancers where TUFM may play functional roles in disease progression.

What methodological approaches enable successful co-localization studies with TUFM antibodies?

Effective TUFM co-localization studies require specialized protocols to accurately visualize mitochondrial localization patterns:

Sample preparation protocols:

• Optimize fixation methods: 4% paraformaldehyde (10-15 minutes) preserves mitochondrial morphology while maintaining TUFM epitope accessibility

• Critical permeabilization: Mild Triton X-100 (0.1-0.2%, 5-10 minutes) provides optimal balance between antibody accessibility and structural preservation

• Blocking strategy: 5% BSA or normal serum from secondary antibody host species (1 hour) minimizes non-specific binding

Co-staining marker selection:

• Primary mitochondrial markers: TOM20, COX IV, or MitoTracker dyes provide reliable mitochondrial boundary definition

• Sequential staining approach: Apply mitochondrial markers first, followed by TUFM antibody to minimize epitope masking

• Spectral separation: Select fluorophores with minimal overlap to enable clear distinction between TUFM and mitochondrial markers

Advanced imaging requirements:

• Confocal microscopy with high NA objectives (≥1.3) to achieve necessary resolution of mitochondrial structures

• Z-stack acquisition (0.2-0.3μm steps) to capture complete mitochondrial networks

• Deconvolution processing to enhance signal-to-noise ratio and improve colocalization precision

• Manders or Pearson coefficient analysis for quantitative colocalization assessment

Validated examples:

• Successful TUFM immunofluorescence has been demonstrated in MCF7 cells with DAPI nuclear counterstaining

• Confocal analysis in U-2 OS cells has confirmed mitochondrial localization patterns

• HepG2 cells show consistent TUFM localization to mitochondria using standardized protocols

These methodological approaches enable reliable visualization and quantification of TUFM's mitochondrial localization patterns in research applications.

How can TUFM antibodies be employed in mitochondrial disorder research models?

TUFM antibodies offer valuable approaches for investigating mitochondrial translation defects and related disorders:

In developmental models:

• Zebrafish studies have demonstrated that TUFM (Mtu1/Trmu) deletion reveals essential roles in mitochondrial biogenesis and hearing function, providing a vertebrate model for studying mitochondrial translation defects

• TUFM antibodies have been used to track expression changes during development and in response to genetic manipulation in these models

For mitochondrial biogenesis assessment:

• Western blotting protocols using TUFM antibodies (1:1000-1:8000 dilution) can quantify changes in mitochondrial translation machinery components following genetic or environmental perturbations

• Correlation with other mitochondrial markers (e.g., OXPHOS components) provides comprehensive assessment of mitochondrial functional states

In toxicological studies:

• TUFM antibodies have helped elucidate mechanisms by which environmental toxins like fluoride and PBDE-47 impair mitochondrial translation, contributing to neurodevelopmental defects

• These approaches help distinguish between direct effects on translation machinery versus secondary mitochondrial dysfunction

For therapeutic development:

• Monitoring TUFM expression following treatment with compounds like ZLN005, which alleviates toxin-induced impairment of mitochondrial translation through the PGC-1α/ERRα axis

• Quantifying restoration of mitochondrial translation capacity as a therapeutic endpoint

These applications demonstrate how TUFM antibodies can serve as valuable tools for understanding the mechanisms underlying mitochondrial disorders and developing potential therapeutic approaches.

What protocols enable successful use of TUFM antibodies in protein interaction studies?

Investigating TUFM's protein interactions requires specialized immunoprecipitation and colocalization approaches:

Optimized Co-Immunoprecipitation protocols:

• Input material preparation: 1.0-3.0 mg total protein lysate from cellular samples provides sufficient starting material

• Antibody amounts: 0.5-4.0 μg antibody per immunoprecipitation reaction

• Pre-clearing step: 1 hour incubation with protein A/G beads alone reduces non-specific binding

• Cross-linking option: Consider DSP or formaldehyde crosslinking to capture transient interactions

• Washing stringency: Optimize salt concentration (150-300mM NaCl) to maintain specific interactions while reducing background

• Elution methods: Compare boiling in SDS buffer versus competitive peptide elution for complex integrity

Validated interaction partners:

• ATG5-ATG12: TUFM recruits this complex to mitochondria during autophagy processes

• NLRX1: TUFM interaction at mitochondria regulates innate immune responses

• Components of the RIGI-MAVS pathway: TUFM serves as a checkpoint in this pathway

Technical verification approaches:

• Reciprocal IP: Confirm interactions by immunoprecipitating with antibodies against interaction partners

• Size exclusion chromatography: Verify complex formation through co-elution profiles

• Proximity ligation assay: Visualize protein interactions in situ with subcellular resolution

• FRET or BRET analysis: For quantitative assessment of interaction dynamics

Published example:
The Samec et al. study demonstrated application of Co-IP techniques with TUFM antibodies to investigate protein interactions relevant to glioblastoma biology .

These protocols enable reliable investigation of TUFM's protein interaction network, providing insight into its diverse roles in mitochondrial translation, autophagy, and immune regulation.

How do functional domains of TUFM affect epitope accessibility and antibody selection strategy?

TUFM's domain architecture significantly influences antibody recognition and experimental applications:

TUFM domain structure and epitope considerations:

• The G domain (guanine nucleotide-binding domain) may undergo conformational changes during GTP binding and hydrolysis, potentially affecting epitope accessibility

• The full protein sequence (452 amino acids) contains specific regions that may be more immunogenic or accessible in different experimental contexts

• N-terminal regions (AA 1-75) contain mitochondrial targeting sequences that may be processed in mature protein

• Middle regions (AA 75-290) are commonly targeted for antibody development due to stable epitope presentation

• C-terminal regions may be involved in protein-protein interactions that could mask epitopes

Strategic antibody selection based on experimental goals:

• For detection of total TUFM: Antibodies targeting preserved central domains (e.g., AA 112-147) provide reliable detection across applications

• For interaction studies: Consider antibodies recognizing C-terminal regions (AA 290-455) that may not interfere with binding partners

• For subcellular localization: N-terminal directed antibodies (AA 1-75) may provide information about processing state

• For distinguishing conformational states: Epitope-specific antibodies may detect GTP-bound versus GDP-bound states

Methodological implications:

• Denaturation sensitivity: Some epitopes may only be accessible in denatured (WB) but not native (IP) conditions

• Fixation effects: Certain epitopes may be masked by specific fixation methods in IF/IHC applications

• Processing considerations: Mitochondrial import may involve cleavage of targeting sequences, potentially affecting N-terminal epitope detection

Understanding these structure-function relationships enables strategic antibody selection for specific experimental objectives and accurate interpretation of results.

What experimental approaches can resolve contradictory TUFM antibody staining patterns across different tissue types?

When faced with inconsistent staining patterns, systematic troubleshooting approaches can resolve contradictions:

Comprehensive validation strategy:

• Multi-antibody confirmation: Test at least two antibodies targeting different TUFM epitopes (e.g., combine 26730-1-AP with 67802-1-Ig)

• Cross-application validation: Compare WB, IHC, and IF results from the same tissue samples to identify technique-specific issues

• Technical replication: Perform independent staining by different investigators using standardized protocols

• Positive control inclusion: Incorporate tissues with established TUFM expression patterns (brain, stomach) in each experiment

Tissue-specific optimization requirements:

• Antigen retrieval comparison: Systematically compare TE buffer pH 9.0 with citrate buffer pH 6.0 for each tissue type

• Fixation assessment: Test multiple fixation conditions (duration, fixative type) that may affect epitope preservation in different tissues

• Block optimization: Tissue-specific autofluorescence or endogenous peroxidase activity may require customized blocking protocols

• Signal amplification: For tissues with lower expression, implement tyramide signal amplification or polymer detection systems

Data interpretation framework:

• Biological versus technical variation: Distinguish between true biological differences and technical artifacts

• mRNA correlation: Compare protein staining patterns with available mRNA expression data across tissues

• Subcellular pattern assessment: Evaluate whether mitochondrial-consistent patterns are observed in positive cells

• Quantitative approach: Implement digital pathology tools for objective pattern comparison

Published examples:
Immunohistochemical analysis has shown consistent TUFM distribution across human duodenum, endometrium, kidney, and testis tissues using multiple independent antibodies (NBP1-84889 and NBP1-84890) .

These systematic approaches enable resolution of contradictory staining patterns and establishment of reliable TUFM expression profiles across diverse tissue types.

How can TUFM antibodies contribute to understanding the intersection between mitochondrial function and innate immunity?

Recent discoveries position TUFM at a critical nexus between mitochondrial translation and immune regulation:

Mechanistic research applications:

• Tracking TUFM-mediated recruitment of ATG5-ATG12 and NLRX1 complexes to mitochondria during immune responses

• Investigating how TUFM serves as a checkpoint in the RIGI-MAVS pathway, potentially modulating type I interferon responses

• Examining TUFM's role in mitophagy regulation during viral infections using dual-labeling approaches

Pathogen interaction studies:

• Bunyavirus SFTSV nucleoprotein has been shown to exploit TUFM-mediated mitophagy to impair antiviral innate immunity

• TUFM antibodies can help track viral protein colocalization with mitochondrial components

• Immunoprecipitation approaches can identify novel viral factors targeting TUFM pathways

Therapeutic implications:

• Monitoring TUFM-dependent mitochondrial translation during inflammatory conditions

• Quantifying mitochondrial stress responses in immune cells under various stimulation conditions

• Evaluating potential therapeutic interventions targeting the TUFM-regulated interface between mitochondria and immunity

These applications help elucidate the fundamental mechanisms by which mitochondrial function influences immune responses, with potential implications for infectious diseases, autoimmune disorders, and inflammatory conditions.

What methodological considerations apply when using TUFM antibodies in cancer research and potential therapeutic development?

TUFM's emerging role in cancer biology presents specific methodological requirements for antibody applications:

For diagnostic biomarker development:

• Tissue microarray analysis using optimized IHC protocols (1:400-1:1600 dilution) can evaluate TUFM expression across tumor types and stages

• Comparison with matched normal tissues provides critical baseline expression data

• Correlation with patient outcomes and clinicopathological features requires standardized scoring systems

• ROC curve analysis establishes sensitivity/specificity parameters for potential diagnostic applications

For therapeutic target validation:

• Nanobody applications: The development of glioblastoma-specific anti-TUFM nanobody (Nb206) demonstrates potential for targeted therapy approaches

• Flow cytometry protocols (0.40 μg per 10^6 cells) can quantify cell surface versus intracellular TUFM exposure in cancer cells

• Antibody internalization studies assess the potential for antibody-drug conjugate development

• In vivo imaging using labeled antibodies can track tumor targeting efficiency

Mechanistic studies in cancer models:

• TUFM antibodies have been employed in studying mitochondrial-targeted HSP90 inhibitors in gliomas

• Co-localization with mitochondrial markers in tumor versus normal cells may reveal cancer-specific alterations in TUFM localization or function

• Western blotting using optimized protocols (1:1000-1:8000) can quantify changes in TUFM expression following therapeutic interventions

These methodological approaches facilitate both basic research into TUFM's role in cancer biology and translational development of diagnostic and therapeutic applications.

What protocol modifications are necessary when applying TUFM antibodies across different model organisms?

Cross-species applications require specific protocol adaptations to account for evolutionary conservation and technical variables:

Rodent model applications:

• TUFM antibodies have been successfully applied to mouse and rat samples, particularly brain tissues

• For mouse samples: Consider using slightly higher antibody concentrations (1.5-2× human recommendations) for Western blotting

• For rat tissues: Antigen retrieval time may need extension (15-20 minutes) compared to human tissues

• Background reduction: Implement mouse-on-mouse blocking systems when using mouse monoclonal antibodies on mouse tissues

Zebrafish model applications:

• TUFM (Mtu1/Trmu) studies in zebrafish have demonstrated roles in mitochondrial biogenesis and hearing function

• Protocol modifications: Extend primary antibody incubation times (overnight at 4°C) and implement specific permeabilization methods for embryos

• Whole-mount applications require specialized clearing techniques to visualize internal structures

• Consider using higher antibody concentrations (2-3× human recommendations) for zebrafish applications

Other model organisms:

• Sequence homology analysis should precede experimental application to non-validated species

• Epitope conservation assessment across species guides antibody selection

• Western blot validation should precede more complex applications in new species

• Control samples from validated species should be included alongside experimental samples

These species-specific modifications enhance successful application of TUFM antibodies across different model organisms while maintaining experimental rigor and data reliability.

What quality control benchmarks should be applied to evaluate TUFM antibody performance in research applications?

Implementing standardized quality control metrics ensures reliable and reproducible TUFM antibody results:

Essential performance criteria:

• Signal-to-noise ratio: Minimum 5:1 for specific TUFM detection versus background in optimized protocols

• Reproducibility: Coefficient of variation <15% across technical replicates in quantitative applications

• Specificity validation: Single band at expected molecular weight (46-50 kDa) in Western blotting applications

• Sensitivity threshold: Detection limit determination for each application (typically 10-50 ng protein for WB)

• Lot-to-lot consistency: <20% variation in titration curves between antibody lots

Application-specific benchmarks:

• WB: Linear dynamic range of at least 2 orders of magnitude in protein amount

• IHC: Minimum 25 positive/negative control tissues validated with consistent staining patterns

• IF: Mitochondrial colocalization coefficient >0.75 with established markers

• FC: Separation index >2.0 between positive and negative populations

• IP: Enrichment factor >10-fold for target protein compared to input

Documentation standards:

• Complete RRID (Research Resource Identifier) citation (e.g., AB_2880616, AB_2918565) in publications

• Explicit protocol parameters including dilutions, incubation times, and buffer compositions

• Inclusion of all validation data in supplementary materials

• Disclosure of optimization procedures and troubleshooting approaches

Adherence to these quality control benchmarks enhances data reliability and experimental reproducibility when working with TUFM antibodies.

What emerging technologies may enhance TUFM antibody applications in future research?

Several cutting-edge technologies are poised to revolutionize TUFM antibody applications:

Super-resolution microscopy approaches:

• STORM/PALM techniques can resolve TUFM localization within mitochondrial substructures beyond diffraction limits

• Expansion microscopy physically enlarges samples to enhance spatial resolution of TUFM distribution

• Lattice light-sheet microscopy enables dynamic visualization of TUFM in living cells with minimal photodamage

Single-cell analysis integration:

• Mass cytometry (CyTOF) incorporates metal-labeled TUFM antibodies for high-dimensional single-cell profiling

• Spatial transcriptomics combined with TUFM immunostaining correlates protein expression with transcriptional profiles

• Microfluidic approaches enable simultaneous protein and RNA quantification in individual cells

Proximity-based interaction mapping:

• BioID or APEX2 fusion proteins can identify proximal proteins to TUFM in living cells

• Protein-fragment complementation assays visualize direct TUFM interactions in real-time

• FRET-based biosensors monitor TUFM conformational changes during functional cycles

Therapeutic applications:

• Antibody-drug conjugates targeting TUFM in cancer cells with mitochondrial dysfunction

• Engineered nanobodies with enhanced tissue penetration for research and potential therapeutic applications

• Intrabody approaches for tracking and potentially modulating TUFM function in living cells

These emerging technologies promise to expand our understanding of TUFM biology and offer new approaches for both basic research and translational applications.